Flavopiridol downregulates hypoxia-mediated hypoxia-inducible factor-1α expression in human glioma cells by a proteasome-independent pathway: Implications for in vivo therapy
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Angiogenesis is a critical step required for sustained tumor growth and tumor progression. The stimulation of endothelial cells by cytokines secreted by tumor cells such as vascular endothelial growth factor (VEGF) induces their proliferation and migration. This is a prominent feature of high-grade gliomas. The secretion of VEGF is greatly upregulated under conditions of hypoxia because of the transcription factor hypoxiainducible factor (HIF)-1alpha, which controls the expression of many genes, allowing rapid adaptation of cells to their hypoxic microenvironment. Flavopiridol, a novel cyclin-dependent kinase inhibitor, has been attributed with antiangiogenic properties in some cancer cell lines by its ability to inhibit VEGF production. Here, we show that flavopiridol treatment of human U87MG and T98G glioma cell lines decreases hypoxia-mediated HIF-1alpha expression, VEGF secretion, and tumor cell migration. These in vitro results correlate with reduced vascularity of intracranial syngeneic GL261 gliomas from animals treated with flavopiridol. In addition, we show that flavopiridol downregulates HIF-1alpha expression in the presence of a proteasome inhibitor, an agent that normally results in the accumulation and overexpression of HIF-1alpha. The potential to downregulate HIF-1alpha expression with flavopiridol treatment in combination with a proteasome inhibitor makes this an extremely attractive anticancer treatment strategy for tumors with high angiogenic activity, such as gliomas.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis
Carmeliet, P., Dor, Y., Herbert, J.-M., Fukumura, D., Brusselmans, K., Dewerchin, M., Neeman, M., Bono, F., Abramovitch, R., Maxwell, P., et al. (1998) · Nature · doi:10.1038/28867 · Cited by 2,502
Cellular and developmental control of O 2 homeostasis by hypoxia-inducible factor 1α
Iyer, N. V., Kotch, L. E., Agani, F., Leung, S. W., Laughner, E., Wenger, R. H., Gassmann, M., Gearhart, J. D., Lawler, A. M., Yu, A. Y., et al. (1998) · Genes & Development · doi:10.1101/gad.12.2.149 · Cited by 2,476 · cited 1×
“HIF-1 has been shown to regulate VEGF expression both in cultured cells and in tumors ( Iyer et al., 1998; Jiang et al., 1997; Maxwell et al., 1997; Ravi et al., 2000).”
BackgroundHuang, L. E., Gu, J., Schau, M., & Bunn, H. F. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.14.7987 · Cited by 2,113 · cited 1×
“The halflife of the HIF-1 protein is extremely short in normoxic conditions but is markedly prolonged during hypoxic stimulation because its normal degradation by the proteasome no longer occurs in hypoxic conditions (Huang et al., 1998; Kallio et al., 1999; Salceda and Caro, 1997).”
BackgroundRegulation of Mammalian O 2 Homeostasis by Hypoxia-Inducible Factor 1
Semenza, G. L. (1999) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.15.1.551 · Cited by 1,914 · cited 4×
“and Semenza, G.L. (1996) Activation of vascular endothelial growth”
BackgroundInfluentialSalceda, S., & Caro, J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.36.22642 · Cited by 1,674
Jiang, B. H., Semenza, G. L., Bauer, C., & Marti, H. H. (1996) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.1996.271.4.c1172 · Cited by 1,213 · cited 1×
“The molecular pathway leading from the sensing of hypoxia to the activation of HIF-1 is critically dependent on the relative abundance and stabilization of the HIF-1 subunit (Huang et al., 1996; Jiang et al., 1996 ).”
BackgroundMaxwell, P. H., Dachs, G. U., Gleadle, J. M., Nicholls, L. G., Harris, A. L., Stratford, I. J., Hankinson, O., Pugh, C. W., & Ratcliffe, P. J. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.15.8104 · Cited by 1,084
Loss of PTEN facilitates HIF-1-mediated gene expression
Zundel, W., Schindler, C., Haas-Kogan, D., Koong, A., Kaper, F., Chen, E., Gottschalk, A. R., Ryan, H. E., Johnson, R. S., Jefferson, A. B., et al. (2000) · Genes & Development · doi:10.1101/gad.14.4.391 · Cited by 840 · cited 1×
“Because p53 and PTEN mutations can affect HIF-1 expression in response to hypoxia (Ravi et al., 2000; Zundel et al., 2000), we selected glioma cell lines on the basis of their differences in p53 (U87MG, wild type; T98G, mutant) and PTEN (U87MG, deletion exon 3; T98G, point mutation codon 42 status) (Ishii et al.”
MethodIshii, N., Maier, D., Merlo, A., Tada, M., Sawamura, Y., Diserens, A., & Van Meir, E. G. (1999) · Brain Pathology · doi:10.1111/j.1750-3639.1999.tb00536.x · Cited by 569 · cited 1×
“Because p53 and PTEN mutations can affect HIF-1 expression in response to hypoxia (Ravi et al., 2000; Zundel et al., 2000), we selected glioma cell lines on the basis of their differences in p53 (U87MG, wild type; T98G, mutant) and PTEN (U87MG, deletion exon 3; T98G, point mutation codon 42 status) ( Ishii et al., 199…”
MethodTumour hypoxia, chemotherapeutic resistance and hypoxia-related therapies
Shannon, A. M., Bouchier-Hayes, D. J., Condron, C. M., & Toomey, D. (2003) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(03)00003-3 · Cited by 559
The hypoxia-inducible factor-1α is a negative factor for tumor therapy
Unruh, A., Ressel, A., Mohamed, H. G., Johnson, R. S., Nadrowitz, R., Richter, E., Katschinski, D. M., & Wenger, R. H. (2003) · Oncogene · doi:10.1038/sj.onc.1206385 · Cited by 334 · cited 2×
“Hypoxia is associated with resistance to cancer therapies (radiation and chemotherapy) (Brown and Giaccia, 1998; Shannon et al., 2003; Unruh et al., 2003 ).”
BackgroundRole of Prolyl Hydroxylation in Oncogenically Stabilized Hypoxia-inducible Factor-1α
Chan, D. A., Sutphin, P. D., Denko, N. C., & Giaccia, A. J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m206922200 · Cited by 264 · cited 1×
“HIF- 1 expression can be stabilized in cells under normoxic conditions by using hypoxia mimetics such as CoCl2 ( Chan et al., 2002; Zagzag et al., 2000).”
Cited by
Gupta, S. C., Kim, J. H., Prasad, S., & Aggarwal, B. B. (2010) · Cancer and Metastasis Reviews · doi:10.1007/s10555-010-9235-2 · Cited by 806
Rohwer, N., & Cramer, T. (2011) · Drug Resistance Updates · doi:10.1016/j.drup.2011.03.001 · Cited by 608
Zimna, A., & Kurpisz, M. (2015) · BioMed Research International · doi:10.1155/2015/549412 · Cited by 604
The use of cobalt chloride as a chemical hypoxia model
Muñoz‐Sánchez, J., & Chánez‐Cárdenas, M. E. (2019) · Journal of Applied Toxicology · doi:10.1002/jat.3749 · Cited by 530
Cairns, R., Papandreou, I., & Denko, N. (2006) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-06-0002 · Cited by 370
Metadata
- Authors
- Newcomb, E. W., Ali, M. A., Schnee, T., Lan, L., Lukyanov, Y., Fowkes, M., Miller, D. C., & Zagzag, D.
- Venue
- Neuro-Oncology
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-07-01
- Volume
- 7
- Issue
- 3
- Pages
- 225-235
- ISSN
- 1522-8517 (ISSN-L)
- 1523-5866
- OpenAlex
- W2155783731
- Cited by
- 72
- References
- 12
- FWCI
- 2.03
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.